February 2, 2022
By Vlad Ratziu (Institute for Cardiometabolsim and Nutrition, Assistance Publique Hôpitaux de Paris, Sorbonne Université, France) and Nicholas Di Prospero (Janssen Pharmaceutical Research and Development, NJ USA). Nonalcoholic fatty liver disease is the most common chronic liver disease and steatohepatitis (a.k.a. nonalcoholic or metabolic steatohepatitis, NASH), its progressive form, is responsible for a growing number...
Read More

Sign up to stay informed

    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at